Category: Epidarex Portfolio News
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation…
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the treatment of spinal fusions and bone defects, announced today it has been granted CE Mark clearance in the European Union…
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel IgE-based platform technology London, November 30th, 2018 – IGEM Therapeutics (IGEM or “the Company”), an immuno-oncology company developing novel immunoglobulin…
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom, 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately. Dr Sixt has 30 years…
Roy Davis appointed as Non-Executive Chairman. Current Chair John Jeans to continue as Non-Executive Director Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the appointment of Roy Davis as non-executive Chairman with immediate effect. John Jeans,…
Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships and develop deep insights into inflammasome biology to drive diversified chemistry into the clinic. Cambridge, UK, Boston, MA and Seattle, WA, 23rd October 2018. NodThera, a biotechnology company…
London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the “Best Start-up Biotech Company” award at the OBN Awards 2018. The award recognises IGEM as a UK registered…
Please see the full list of nominees and additional information regarding the awards here.